Pharmacokinetic and pharmacodynamic aspects of antibiotic use in high-risk populations

被引:22
作者
Bergman, Scott J. [1 ]
Speil, Cristian
Short, Michael
Koirala, Janak
机构
[1] So Illinois Univ, Sch Pharm, Dept Pharm Practice, Edwardsville, IL 62026 USA
[2] So Illinois Univ, Sch Med, Div Infect Dis, Springfield, IL USA
[3] Mem Med Ctr, Dept Pharm Serv, Springfield, IL 62781 USA
关键词
D O I
10.1016/j.idc.2007.07.004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The study of pharmacokinetics includes the absorption, distribution, metabolism, and elimination of drugs. The pharmacologic effect that a medication has on the body is known as pharmacodynamics. With antimicrobials, pharmacokinetic and pharmacodynamic parameters become especially important because of the association between host drug concentrations, microorganism eradication, and resistance. This article focuses on the pharmacokinetic changes that can occur with antimicrobials when they are used in patients at high risk of infections and how they influence pharmacodynamic effects. The populations described here include patients with obesity and diabetes mellitus, renal or hepatic failure, chronic lung disease, severe burns, and long-term prosthetic devices and the elderly.
引用
收藏
页码:821 / +
页数:27
相关论文
共 146 条
[1]   KINETICS OF RIFAMPICIN AND ISONIAZID ADMINISTERED ALONE AND IN COMBINATION TO NORMAL SUBJECTS AND PATIENTS WITH LIVER-DISEASE [J].
ACOCELLA, G ;
BONOLLO, L ;
TENCONI, LT ;
GARIMOLDI, M ;
MAINARDI, M ;
NICOLIS, FB .
GUT, 1972, 13 (01) :47-+
[2]   INTRAVENOUS CIPROFLOXACIN DISPOSITION IN OBESITY [J].
ALLARD, S ;
KINZIG, M ;
BOIVIN, G ;
SORGEL, F ;
LEBEL, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (04) :368-373
[3]   Clinical pharmacodynamics of quinolones [J].
Ambrose, PG ;
Bhavnani, SM ;
Owens, RC .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2003, 17 (03) :529-+
[4]   Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin [J].
Anderl, JN ;
Franklin, MJ ;
Stewart, PS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) :1818-1824
[5]   Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis [J].
Ariano, RE ;
Fine, A ;
Sitar, DS ;
Rexrode, S ;
Zelenitsky, SA .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (04) :681-687
[6]   EFFECT OF ANTIBIOTICS ON NONGROWING PLANKTONIC CELLS AND BIOFILMS OF ESCHERICHIA-COLI [J].
ASHBY, MJ ;
NEALE, JE ;
KNOTT, SJ ;
CRITCHLEY, IA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 33 (03) :443-452
[7]   EFFECT OF CIRRHOSIS ON DISPOSITION AND ELIMINATION OF CLINDAMYCIN [J].
AVANT, GR ;
SCHENKER, S ;
ALFORD, RH .
AMERICAN JOURNAL OF DIGESTIVE DISEASES, 1975, 20 (03) :223-230
[8]   AZITHROMYCIN - THE 1ST AZALIDE ANTIBIOTIC [J].
BALLOW, CH ;
AMSDEN, GW .
ANNALS OF PHARMACOTHERAPY, 1992, 26 (10) :1253-1261
[9]   PHARMACOKINETICS OF ERYTHROMYCIN IN PATIENTS WITH SEVERE CIRRHOSIS - RESPECTIVE INFLUENCE OF DECREASED SERUM BINDING AND IMPAIRED LIVER METABOLIC CAPACITY [J].
BARRE, J ;
MALLAT, A ;
ROSENBAUM, J ;
DEFORGES, L ;
HOUIN, G ;
DHUMEAUX, D ;
TILLEMENT, JP .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 23 (06) :753-757
[10]   Use of vancomycin in high-flux hemodialysis: Experience with 130 courses of therapy [J].
Barth, RH ;
DeVincenzo, N .
KIDNEY INTERNATIONAL, 1996, 50 (03) :929-936